Gossamer Bio Inc., a clinical biopharmaceutical company, has entered into a global collaboration agreement with the Chiesi Group to jointly develop seralutinib for the treatment of pulmonary arterial hypertension (PAH). This partnership aims to advance seralutinib as a potential first-in-class treatment option, with the companies focusing on Functional Class II and III PAH patients. The collaboration is currently centered on the ongoing Phase 3 PROSERA Study, which recently completed enrollment. This study is a critical step in evaluating the efficacy of seralutinib and is expected to yield topline results in February 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。